; (B) stakeholders with expertise in the research and development of novel medical products, including manufacturers of such products; (C) representatives of commercial health insurance payers; (D) stakeholders with expertise in the administration and use of novel medical products, including physicians; and (E) stakeholders representing patients and with expertise in the utilization of patient experience data in medical product development. (3) Topics The public meeting shall include a discussion of— (A) the status of the drug and medical device development pipeline related to the availability of novel medical products; (B) the anticipated expertise necessary to review the safety and effectiveness of such products at the Food and Drug Administration and current gaps in such expertise, if any; (C) the expertise necessary to make coding, coverage, and payment decisions with respect to such products within the Centers for Medicare & Medicaid Services, and current gaps in such expertise, if any; (D) trends in the differences in the data necessary to determine the safety and effectiveness of a novel medical product and the data necessary to determine whether a novel medical product meets the reasonable and necessary requirements for coverage and payment under title XVIII of the Social Security Act pursuant to section 1862(a)(1)(A) of such Act ( 42 U.S.C. 1395y(a)(1)(A) ); (E) the availability of information for sponsors of such novel medical products to meet each of those requirements